Annual CFF
$6.91 M
+$6.79 M+5856.90%
31 December 2023
Summary:
Aptose Biosciences annual cash flow from financing activities is currently $6.91 million, with the most recent change of +$6.79 million (+5856.90%) on 31 December 2023. During the last 3 years, it has fallen by -$51.90 million (-88.25%). APTO annual CFF is now -93.32% below its all-time high of $103.45 million, reached on 31 December 2019.APTO Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$10.01 M
+$5.25 M+110.52%
30 September 2024
Summary:
Aptose Biosciences quarterly cash flow from financing activities is currently $10.01 million, with the most recent change of +$5.25 million (+110.52%) on 30 September 2024. Over the past year, it has increased by +$5.11 million (+104.16%). APTO quarterly CFF is now -86.41% below its all-time high of $73.64 million, reached on 31 December 2019.APTO Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$27.46 M
+$5.11 M+22.84%
30 September 2024
Summary:
Aptose Biosciences TTM cash flow from financing activities is currently $27.46 million, with the most recent change of +$5.11 million (+22.84%) on 30 September 2024. Over the past year, it has increased by +$21.36 million (+349.70%). APTO TTM CFF is now -79.26% below its all-time high of $132.41 million, reached on 30 September 2020.APTO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
APTO Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +5856.9% | +104.2% | +349.7% |
| 3 y3 years | -88.3% | +100.0% | +10000.0% |
| 5 y5 years | -75.2% | +10000.0% | -23.0% |
APTO Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -88.3% | +5856.9% | -15.5% | at high | >+9999.0% | |
| 5 y | 5 years | -93.3% | +5856.9% | -86.4% | -79.3% | >+9999.0% | |
| alltime | all time | -93.3% | +690.9% | -86.4% | +411.3% | -79.3% | +930.7% |
Aptose Biosciences Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $10.01 M(+110.5%) | $27.46 M(+22.8%) |
| June 2024 | - | $4.75 M(-59.9%) | $22.36 M(+19.5%) |
| Mar 2024 | - | $11.85 M(+1287.2%) | $18.71 M(+170.7%) |
| Dec 2023 | $6.91 M(+5856.9%) | $854.00 K(-82.6%) | $6.91 M(+13.1%) |
| Sept 2023 | - | $4.90 M(+344.0%) | $6.11 M(+398.1%) |
| June 2023 | - | $1.10 M(+2108.0%) | $1.23 M(+711.9%) |
| Mar 2023 | - | $50.00 K(-2.0%) | $151.00 K(+30.2%) |
| Dec 2022 | $116.00 K(-48.7%) | $51.00 K(+142.9%) | $116.00 K(-11.5%) |
| Sept 2022 | - | $21.00 K(-27.6%) | $131.00 K(+19.1%) |
| June 2022 | - | $29.00 K(+93.3%) | $110.00 K(-33.7%) |
| Mar 2022 | - | $15.00 K(-77.3%) | $166.00 K(-26.5%) |
| Dec 2021 | $226.00 K(-99.6%) | $66.00 K(>+9900.0%) | $226.00 K(+11.9%) |
| Sept 2021 | - | $0.00(-100.0%) | $202.00 K(-99.7%) |
| June 2021 | - | $85.00 K(+13.3%) | $58.48 M(+0.1%) |
| Mar 2021 | - | $75.00 K(+78.6%) | $58.45 M(-0.6%) |
| Dec 2020 | $58.81 M(-43.2%) | $42.00 K(-99.9%) | $58.81 M(-55.6%) |
| Sept 2020 | - | $58.28 M(>+9900.0%) | $132.41 M(+78.6%) |
| June 2020 | - | $46.00 K(-89.4%) | $74.14 M(-24.1%) |
| Mar 2020 | - | $436.00 K(-99.4%) | $97.71 M(-5.6%) |
| Dec 2019 | $103.45 M(+271.2%) | $73.64 M(>+9900.0%) | $103.45 M(+190.2%) |
| Sept 2019 | - | $17.00 K(-99.9%) | $35.65 M(-4.3%) |
| June 2019 | - | $23.61 M(+282.2%) | $37.24 M(+47.8%) |
| Mar 2019 | - | $6.18 M(+5.8%) | $25.19 M(-9.6%) |
| Dec 2018 | $27.87 M(+103.2%) | $5.84 M(+263.1%) | $27.87 M(+9.1%) |
| Sept 2018 | - | $1.61 M(-86.1%) | $25.55 M(-1.5%) |
| June 2018 | - | $11.57 M(+30.6%) | $25.94 M(+37.3%) |
| Mar 2018 | - | $8.86 M(+151.9%) | $18.90 M(+37.8%) |
| Dec 2017 | $13.72 M(+139.6%) | $3.52 M(+75.8%) | $13.72 M(+1.5%) |
| Sept 2017 | - | $2.00 M(-55.9%) | $13.52 M(+10.6%) |
| June 2017 | - | $4.53 M(+23.2%) | $12.23 M(+30.1%) |
| Mar 2017 | - | $3.68 M(+10.8%) | $9.40 M(+64.2%) |
| Dec 2016 | $5.73 M(+629.4%) | $3.32 M(+370.0%) | $5.73 M(+125.3%) |
| Sept 2016 | - | $706.10 K(-58.5%) | $2.54 M(+39.7%) |
| June 2016 | - | $1.70 M(>+9900.0%) | $1.82 M(+422.7%) |
| Mar 2016 | - | $0.00(-100.0%) | $348.00 K(-55.7%) |
| Dec 2015 | $785.00 K(-86.6%) | $134.70 K(-901.8%) | $785.00 K(+20.7%) |
| Sept 2015 | - | -$16.80 K(-107.3%) | $650.30 K(-2.5%) |
| June 2015 | - | $230.10 K(-47.3%) | $667.10 K(-97.4%) |
| Mar 2015 | - | $437.00 K(-98.3%) | $25.61 M(-27.3%) |
| Dec 2014 | $5.86 M(-83.4%) | - | - |
| May 2014 | $35.22 M(+573.2%) | $25.17 M(+273.2%) | $35.22 M(+251.8%) |
| Feb 2014 | - | $6.74 M(+173.3%) | $10.01 M(+222.5%) |
| Nov 2013 | - | $2.47 M(+196.3%) | $3.10 M(+389.0%) |
| Aug 2013 | - | $832.90 K(-2452.8%) | $634.70 K(-87.9%) |
| May 2013 | $5.23 M(+98.2%) | -$35.40 K(-78.0%) | $5.23 M(-9.4%) |
| Feb 2013 | - | -$161.20 K(>+9900.0%) | $5.77 M(-8.4%) |
| Nov 2012 | - | -$1600.00(-100.0%) | $6.30 M(+2.3%) |
| Aug 2012 | - | $5.43 M(+970.5%) | $6.16 M(+133.4%) |
| May 2012 | $2.64 M(-55.8%) | $507.20 K(+37.9%) | $2.64 M(+23.4%) |
| Feb 2012 | - | $367.80 K(-354.2%) | $2.14 M(-41.0%) |
| Nov 2011 | - | -$144.70 K(-107.6%) | $3.62 M(-54.1%) |
| Aug 2011 | - | $1.91 M(>+9900.0%) | $7.90 M(+32.4%) |
| May 2011 | $5.97 M | $7000.00(-99.6%) | $5.97 M(-0.8%) |
| Feb 2011 | - | $1.85 M(-55.2%) | $6.01 M(+44.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Nov 2010 | - | $4.13 M(<-9900.0%) | $4.15 M(+105.7%) |
| Aug 2010 | - | -$26.40 K(-149.0%) | $2.02 M(-272.6%) |
| May 2010 | -$1.17 M(-133.5%) | $53.90 K(-809.2%) | -$1.17 M(+91.3%) |
| Feb 2010 | - | -$7600.00(-100.4%) | -$611.40 K(-22.5%) |
| Nov 2009 | - | $2.00 M(-162.2%) | -$788.70 K(-76.1%) |
| Aug 2009 | - | -$3.21 M(-625.2%) | -$3.31 M(-194.7%) |
| May 2009 | $3.49 M(-52.5%) | $612.10 K(-431.0%) | $3.49 M(+25.9%) |
| Feb 2009 | - | -$184.90 K(-64.3%) | $2.77 M(-10.5%) |
| Nov 2008 | - | -$518.30 K(-114.5%) | $3.10 M(-26.3%) |
| Aug 2008 | - | $3.58 M(-3465.0%) | $4.21 M(-42.7%) |
| May 2008 | $7.35 M(-24.3%) | -$106.50 K(-175.3%) | $7.35 M(-4.2%) |
| Feb 2008 | - | $141.50 K(-76.0%) | $7.67 M(+12.4%) |
| Nov 2007 | - | $590.40 K(-91.2%) | $6.82 M(+15.7%) |
| Aug 2007 | - | $6.73 M(+3062.0%) | $5.90 M(-39.3%) |
| May 2007 | $9.72 M(>+9900.0%) | $212.70 K(-130.2%) | $9.72 M(+2.2%) |
| Feb 2007 | - | -$705.40 K(+111.5%) | $9.50 M(-6.9%) |
| Nov 2006 | - | -$333.50 K(-103.2%) | $10.21 M(-3.2%) |
| Aug 2006 | - | $10.54 M(>+9900.0%) | $10.54 M(>+9900.0%) |
| May 2006 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(-100.0%) |
| Feb 2006 | - | $0.00(0.0%) | $3.86 M(-50.4%) |
| Nov 2005 | - | $0.00(0.0%) | $7.78 M(-30.5%) |
| Aug 2005 | - | $0.00(-100.0%) | $11.19 M(-0.0%) |
| May 2005 | $11.20 M(-49.2%) | $3.86 M(-1.5%) | $11.20 M(+62.2%) |
| Feb 2005 | - | $3.92 M(+14.7%) | $6.91 M(+185.8%) |
| Nov 2004 | - | $3.42 M(>+9900.0%) | $2.42 M(+402.9%) |
| Aug 2004 | - | $4000.00(-100.9%) | $480.40 K(-97.8%) |
| May 2004 | $22.06 M(+6335.9%) | -$432.80 K(-24.3%) | $22.06 M(-3.3%) |
| Feb 2004 | - | -$571.80 K(-138.6%) | $22.81 M(-2.5%) |
| Nov 2003 | - | $1.48 M(-93.1%) | $23.40 M(+6.8%) |
| Aug 2003 | - | $21.58 M(+6525.6%) | $21.92 M(+6296.0%) |
| May 2003 | $342.70 K(-62.3%) | $325.70 K(+2226.4%) | $342.70 K(+482.8%) |
| Feb 2003 | - | $14.00 K(>+9900.0%) | $58.80 K(-88.8%) |
| Nov 2002 | - | $0.00(-100.0%) | $523.60 K(-40.9%) |
| Aug 2002 | - | $3000.00(-92.8%) | $885.60 K(-2.5%) |
| May 2002 | $908.60 K(-32.3%) | $41.80 K(-91.3%) | $908.60 K(-28.2%) |
| Feb 2002 | - | $478.80 K(+32.3%) | $1.27 M(-14.3%) |
| Nov 2001 | - | $362.00 K(+1292.3%) | $1.48 M(+19.7%) |
| Aug 2001 | - | $26.00 K(-93.5%) | $1.23 M(-8.1%) |
| May 2001 | $1.34 M(-96.7%) | $399.30 K(-42.1%) | $1.34 M(-93.6%) |
| Feb 2001 | - | $689.60 K(+480.0%) | $20.84 M(-17.8%) |
| Nov 2000 | - | $118.90 K(-12.0%) | $25.35 M(-38.0%) |
| Aug 2000 | - | $135.10 K(-99.3%) | $40.92 M(+0.3%) |
| May 2000 | $40.78 M(+472.7%) | $19.90 M(+283.1%) | $40.78 M(+52.1%) |
| Feb 2000 | - | $5.19 M(-66.9%) | $26.81 M(+19.2%) |
| Nov 1999 | - | $15.69 M(>+9900.0%) | $22.48 M(+230.4%) |
| Aug 1999 | - | $0.00(-100.0%) | $6.80 M(-4.4%) |
| May 1999 | $7.12 M(>+9900.0%) | $5.93 M(+583.2%) | $7.12 M(+496.8%) |
| Feb 1999 | - | $867.70 K(+9435.2%) | $1.19 M(+266.6%) |
| Nov 1998 | - | $9100.00(-97.1%) | $325.50 K(+2.9%) |
| Aug 1998 | - | $316.40 K(>+9900.0%) | $316.40 K(>+9900.0%) |
| May 1998 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Feb 1998 | - | $0.00(0.0%) | $0.00(0.0%) |
| Nov 1997 | - | $0.00(0.0%) | $0.00(0.0%) |
| Aug 1997 | - | $0.00 | $0.00 |
| May 1997 | $7.62 M | - | - |
FAQ
- What is Aptose Biosciences annual cash flow from financing activities?
- What is the all time high annual CFF for Aptose Biosciences?
- What is Aptose Biosciences annual CFF year-on-year change?
- What is Aptose Biosciences quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Aptose Biosciences?
- What is Aptose Biosciences quarterly CFF year-on-year change?
- What is Aptose Biosciences TTM cash flow from financing activities?
- What is the all time high TTM CFF for Aptose Biosciences?
- What is Aptose Biosciences TTM CFF year-on-year change?
What is Aptose Biosciences annual cash flow from financing activities?
The current annual CFF of APTO is $6.91 M
What is the all time high annual CFF for Aptose Biosciences?
Aptose Biosciences all-time high annual cash flow from financing activities is $103.45 M
What is Aptose Biosciences annual CFF year-on-year change?
Over the past year, APTO annual cash flow from financing activities has changed by +$6.79 M (+5856.90%)
What is Aptose Biosciences quarterly cash flow from financing activities?
The current quarterly CFF of APTO is $10.01 M
What is the all time high quarterly CFF for Aptose Biosciences?
Aptose Biosciences all-time high quarterly cash flow from financing activities is $73.64 M
What is Aptose Biosciences quarterly CFF year-on-year change?
Over the past year, APTO quarterly cash flow from financing activities has changed by +$5.11 M (+104.16%)
What is Aptose Biosciences TTM cash flow from financing activities?
The current TTM CFF of APTO is $27.46 M
What is the all time high TTM CFF for Aptose Biosciences?
Aptose Biosciences all-time high TTM cash flow from financing activities is $132.41 M
What is Aptose Biosciences TTM CFF year-on-year change?
Over the past year, APTO TTM cash flow from financing activities has changed by +$21.36 M (+349.70%)